Evaluation of oral erosion and prevention by Hangeshashinto in chemotherapy for esophageal cancer

Evaluation of oral erosion and prevention by Hangeshashinto in chemotherapy for esophageal cancer - Evaluation of oral erosion and prevention by Hangeshashinto in chemotherapy for esophageal cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006201

Enrollment

Registered

2011-08-19

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

Hangeshyashinto none

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) squamous cell carcinoma 2) patients to undergo 5-FU(800mg/m2x5days and CDDP 80mg/m2) 3) PS 0-2 4) possible in oral intake of Hangeshashinto 5) 20-year-old or older 6) Adequate organ functions 7) estimated 12 weeks or longer survival 8) Written informed consent

Exclusion criteria

Exclusion criteria: 1) no prior history of allergy in Hangeshashinto 2) patients to undergo other regimen of chemotherapy 3) no prior other Kanpo-drugs administered 4) severe organ failures 5) no prior history of opioids or steroidal treatments 6) active infection 7) concomitant active cancers 8) severe allergy for other drugs 9) patients who want to be pregnant or pregnant woman 10) severe constipation 11) pulmonary fibrosis 12) severe pshychological disorder 13) inappropriate cases for a clinical trials

Design outcomes

Primary

Measure	Time frame
Rate of oral erosion	—

Countries

Japan

Contacts

Public ContactYasunori Akutsu

Chiba University Frontier Surgery

yakuts@faculty.chiba-u.jp043-226-2110

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026